We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $50.84 in the latest trading session, marking a -0.88% move from the prior day. This change lagged the S&P 500's 2.37% gain on the day. Elsewhere, the Dow gained 2.47%, while the tech-heavy Nasdaq lost 0.02%.
Heading into today, shares of the company had lost 20.97% over the past month, lagging the Medical sector's loss of 2.47% and the S&P 500's loss of 4.82% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.30, down 37.72% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 million, up 329.88% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$9.17 per share and revenue of $14.21 million. These totals would mark changes of -295.11% and -98.45%, respectively, from last year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.99% higher. CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 54, putting it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $50.84 in the latest trading session, marking a -0.88% move from the prior day. This change lagged the S&P 500's 2.37% gain on the day. Elsewhere, the Dow gained 2.47%, while the tech-heavy Nasdaq lost 0.02%.
Heading into today, shares of the company had lost 20.97% over the past month, lagging the Medical sector's loss of 2.47% and the S&P 500's loss of 4.82% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.30, down 37.72% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 million, up 329.88% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$9.17 per share and revenue of $14.21 million. These totals would mark changes of -295.11% and -98.45%, respectively, from last year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.99% higher. CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 54, putting it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.